PT-141 Dose: What the FDA-Approved Label Says

The standard PT-141 dose is 1.75 mg injected subcutaneously, no more than once every 24 hours and no more than eight times per month. Bremelanotide, sold under the brand name Vyleesi, is FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder. There is no stronger dose that works better — the label sets one fixed amount because larger and repeated doses produced more nausea, not more benefit.

What the FDA-Approved PT-141 Dose Looks Like

Vyleesi is a single-use autoinjector prefilled with 1.75 mg of bremelanotide. It is injected under the skin of the thigh or abdomen. The label caps use at one dose per 24 hours and eight doses per 30 days.

• Approved dose: 1.75 mg subcutaneously
• Frequency: once per 24 hours, maximum 8 doses per month
• Timing: about 45 minutes before anticipated sexual activity
• Food: may be taken with or without food
• Alcohol: avoid drinking on days when a dose is used

The 1.75 mg dose is not a starting point that gets titrated upward. Clinical trials that tested higher or repeated exposure reported more gastrointestinal side effects rather than an improved response. That is why the approved PT-141 dosage stays fixed.

How PT-141 Doses Compare by Route

Only one bremelanotide product has been reviewed by the FDA, but compounded injections and nasal sprays are widely discussed online. Dose equivalence between these routes has never been established.

Route	Commonly reported dose	Onset	Regulatory status
Subcutaneous injection (Vyleesi)	1.75 mg	About 45 minutes	FDA-approved for premenopausal women with HSDD
Compounded injection vial	Varies; requires reconstitution	Similar to injection	Not FDA-approved
Compounded nasal spray	Often listed as 10 mg or more	Roughly 30 to 60 minutes	Not FDA-approved; absorption varies
Oral or sublingual	Not established	Unknown	Not FDA-approved; poor bioavailability

Some suppliers list a pt-141 bremelanotide injection 20mg vial that must be mixed with water before use. That number describes the entire vial, not a single dose, and math errors with reconstituted peptides are a real risk.

PT-141 Dosing in Men and Off-Label Use

Bremelanotide is not FDA-approved for men, and no official male dose exists. Early studies in men used injected doses around 1.75 mg and intranasal doses of 10 mg or more, but those trials were small and short.

Off-label use means the dose, monitoring, and product quality fall outside FDA oversight. A clinician who knows the drug is the only reasonable source of guidance for anyone considering it.

Timing: Onset and How Long Effects Last

The question pt-141 how long does it take to work has a practical answer in the label: inject about 45 minutes before anticipated sexual activity. Some users report noticing effects sooner, and others notice nothing at all.

A separate question — how long does pt-141 last — is harder to pin down. Patient reports describe a window of roughly one to six hours.

Effects from a single dose generally fade within a few hours, and the label does not allow a second injection in the same 24-hour period. Taking more to extend the window increases the chance of nausea and blood pressure changes.

Side Effects and Safety at Any Dose

Nausea is the most common side effect and was reported by roughly 40% of participants in the trials that supported approval. Flushing, headache, and injection site reactions are also frequent.

• Nausea and vomiting
• Flushing, headache, and dizziness
• Injection site pain, bruising, or itching
• Temporary increases in blood pressure and heart rate
• Focal hyperpigmentation, including darkening of the face, gums, or breasts, which can persist after the drug is stopped

Bremelanotide is not recommended for people with uncontrolled high blood pressure or known cardiovascular disease, and it should not be used during pregnancy. Drinking alcohol on a dosing day raises the odds of nausea and blood pressure changes.

Prescriptions, Legality, and Key Takeaways

In the United States, do you need a prescription for pt-141? Yes. Bremelanotide is a prescription-only medicine, and no over-the-counter version has been approved.

Legally, where to buy pt-141 means a licensed US pharmacy with a valid prescription from a clinician. Vials and sprays sold as research chemicals are not intended for human use, and compounded bremelanotide has not been reviewed by the FDA for safety, potency, or sterility.

• The FDA-approved PT-141 dose is 1.75 mg injected under the skin, once per 24 hours.
• No more than eight doses should be used in a 30-day period.
• Bremelanotide is not approved for men or for anyone under 18.
• Compounded nasal sprays and vials have unpredictable dosing and are not FDA-approved.
• Nausea, flushing, and blood pressure changes are the main safety concerns.

Anyone with questions about their own dose should talk with a licensed healthcare professional instead of adjusting based on internet reports.

COMMON QUESTIONS

Frequently Asked Questions

What is the standard PT-141 dose?

The FDA-approved dose is 1.75 mg injected subcutaneously, with a maximum of one dose every 24 hours and no more than eight doses in 30 days. This amount is fixed and is not increased over time. Bremelanotide is approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder.

How long does a PT-141 dose take to work?

The label directs users to inject about 45 minutes before anticipated sexual activity, and many people report effects within that window. Individual response varies widely, and some users notice little or no effect. Effects typically fade within a few hours, and a second dose in the same 24-hour period is not recommended.

Can I buy PT-141 without a prescription?

No. Bremelanotide is a prescription-only medication in the United States, and no over-the-counter form exists. Compounded nasal sprays and injection vials sold online are not FDA-approved and may contain inconsistent amounts of the drug.